TG Therapeutics (TGTX) moved into the spotlight after management lifted full year 2026 earnings guidance, raising its total global revenue target to about US$1b from roughly US$950m.
The revised outlook arrived alongside fresh recognition, with TG Therapeutics ranking fifth on Deloitte's 2026 Technology Fast 500 list in North America, tied to BRIUMVI's contribution in multiple sclerosis treatment.
Investors have chased TG Therapeutics higher over the year, with the share price up 121.58% year to date and supported by a 3 year total shareholder return above 4x. The latest 1 day dip of 1.88% barely dents a 30 day gain of 18.98%, as guidance and earnings news keep momentum building.
Scan other fast-growing healthcare and biotech stocks showing similar momentum to TG Therapeutics by exploring the curated 36 healthcare AI stocks list.
TG Therapeutics now has a bigger guidance target and a stock that has already run hard. The business looks stronger. The real issue is whether the current price still leaves enough value on the table.
Analysts on Simply Wall St see fair value for TG Therapeutics at about $77.83, above the last close of $64.88, and frame that gap using the analyst consensus Narrative on Simply Wall St, which ties forecasts, cash flows and risks into one view.
The main thing that has to go right is successful execution on subcutaneous BRIUMVI and new indications so the company can extend its current anti-CD20 position and maintain high-margin operations.
The planned launch of subcutaneous BRIUMVI remains a key upcoming catalyst, as it targets the 35 to 40% of the anti CD20 multiple sclerosis market that is currently in self administered products where TG Therapeutics does not yet participate, which could materially affect future revenue and earnings.
See why 76 investors see TG Therapeutics as 17% undervalued.
Result: Fair Value of $77.83 (UNDERVALUED)
Still, the TG Therapeutics story can change quickly if the investigation into potential fiduciary breaches escalates, or if heavy manufacturing spending continues to squeeze profitability.
Find out about the key risks to this TG Therapeutics narrative.
There is a catch. While the Simply Wall St analyst narrative leans on future earnings and cash flows to support a fair value of $77.83, the current P/E of 85.7x tells a much tougher story. That multiple is far above the US Biotechs industry at 16.1x, the peer group at 46.9x, and the fair ratio estimate of 32.3x.
In practice, that means a lot of optimism is already baked into TG Therapeutics at today’s $64.88 price, even if the DCF style work flags upside. If sentiment cools or execution stumbles, the key question is whether the share price would converge toward the richer narrative or toward the lower fair ratio instead.
See what the numbers say about this price — find out in our valuation breakdown.
Mixed feelings on TG Therapeutics so far. Momentum is strong and the valuation debate is loud, so move quickly, review the data yourself, and weigh both sides with the 2 key rewards and 2 important warning signs.
If TG Therapeutics has your attention, do not stop here. Broaden your watchlist and give yourself more quality options before the next move catches you off guard.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com